Shawn Tomasello
CIK 1617239 · Chief Commercial Officer · last filed 2026-06-18
Shawn Tomasello is a Chief Commercial Officer who has filed 52 SEC Form 4 insider transactions across 10 companies since 2015. The most recent filing, for FDMT, was dated Jun 18, 2026. Across all open-market trades the lifetime net is −$990.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $70.7K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$70.7K
10
52
-$990.2K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FDMT | Director | — | $9.85 | — | $0 | 6 | 2026-06-18 |
| CABA | Director | 22,725 | $2.73 | $62.0K | $50.3K | 6 | 2026-06-10 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | Director | 3,043 | $9.81 | $29.9K | $0 | 4 | 2024-06-07 |
| Gamida Cell Ltd. (GMDA) Delisted | Director | 241,977 | $0.03 | $7.9K | $15.0K | 7 | 2024-02-02 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | Director | — | $1.48 | — | $0 | 4 | 2023-06-01 |
| URGN | Director | — | $40.88 | — | $0 | 3 | 2021-06-09 |
| Principia Biopharma Inc. (PRNB) Delisted | Director | — | — | — | $0 | 4 | 2020-09-28 |
| ABEO | Director | 1,438 | $6.02 | $8.7K | $0 | 1 | 2020-05-22 |
| Diplomat Pharmacy, Inc. (DPLO) Delisted | Director | 33,259 | — | — | -$51.1K | 8 | 2020-02-10 |
| Kite Pharma, Inc. (KITE) Delisted | Chief Commercial Officer | 61,068 | — | — | -$1.00M | 4 | 2017-09-27 |
Recent Filings
52 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-18 | FDMT | Grant (A) | — | $0 | EDGAR |
| 2026-06-10 | CABA | Grant (A) | — | $0 | EDGAR |
| 2026-01-21 | CABA | Buy (P) | +22,725 | $50.3K | EDGAR |
| 2025-06-20 | FDMT | Grant (A) | — | $0 | EDGAR |
| 2025-06-09 | CABA | Grant (A) | — | $0 | EDGAR |
| 2025-05-19 | CABA | Mixed | — | $0 | EDGAR |
| 2024-06-07 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +35,000 | $0 | EDGAR |
| 2024-06-04 | CABA | Grant (A) | — | $0 | EDGAR |
| 2024-05-23 | FDMT | Grant (A) | — | $0 | EDGAR |
| 2024-02-02 | Gamida Cell Ltd. (GMDA) Delisted | Grant (A) | +200,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.